人参皂苷Rg3负载PCL-PEG纳米系统在卵巢癌中的优化研究
Improvements on Ginsenoside Rg3 Nanopreparations Delivery Systems in Ovarian Cancer
DOI: 10.12677/ACM.2023.133650, PDF,   
作者: 杨 瑾, 邹 丹, 梁 蕾, 武艳玲, 张焕灵, 黄树峰*:深圳市前海蛇口自贸区医院,南山区重点学科,广东 深圳
关键词: 人参皂苷Rg3脂质体纳米粒微乳Ginsenoside Rg3 Liposome Nanoparticles Microemulsion
摘要: 目的:为了提高人参皂苷Rg3的有效性和靶向性,研究人参皂苷Rg3脂质体、纳米粒及微乳的制备及其在小鼠体内组织分布的差异,比较各类纳米制剂的靶向特异性。方法:采用薄膜超声分散法、纳米沉淀法、微乳法分别制备人参皂苷Rg3脂质体及人参皂苷Rg3PLGA纳米粒,人参皂苷Rg3微乳粒,通过比较三种方案效果,制定优化方案。结果:1) 磷脂、胆固醇、人参皂苷Rg3制备的脂质体平均粒径为111.8 nm,Zeta电位为−38.67 mV,。2) PLGA浓度为10 mg∙mL−1,人参皂苷Rg3浓度为3 mg∙mL−1,有机相与水相体积比为1:3。制备的纳米粒平均粒径为186.1 nm,Zeta电位为−29.56 mV。3) 油酸乙酯、EL35、PEG400与水的最佳质量比为8.25:12:4.75:75,平均粒径为60.50 nm,Zeta电位为−15.63 mV。结论:三种人参皂苷Rg3纳米制剂的工艺方法均简便、稳定可行。微乳法分别制备人参皂苷Rg3脂质体分层结构最明显。
Abstract: Objective: To improve the effectiveness and targeting of ginsenoside Rg3, to study the preparation and distribution of ginsenoside Rg3 liposomes, nanoparticles and microemulsion in mice, and to compare the targeting specificity of various nano preparations. Methods: Ginsenoside Rg3 lipo-somes, ginsenoside Rg3 PLGA nanoparticles and ginsenoside Rg3 microemulsion granules were prepared by ultrasonic film dispersion method, nano precipitation method and microemulsion method respectively. The optimization scheme was developed by comparing the effect of the three schemes. Results: 1) Using chloroform-ethanol (1:1) as solvent, the mass ratio of phospholipid, cho-lesterol and ginsenoside Rg3 was 4:2:1, the average particle size of the liposome was 111.8 nm, the Zeta potential was −38.67 mV, and the encapsulation rate was 87.85%. 2) PLGA conase tcentration was 10 mg∙mL−1, human ginseng saponin Rg3 concentration was 3 mg∙mL−1, organic pho water phase volume ratio was 1:3. The average particle size of the prepared nanoparticles was 186.1 nm, the Zeta potential was −29.56 mV, and the encapsulation rate was 87.29%. 3) The optimum mass ratio of ethyl oleate, EL35, PEG400 to water was 8.25:12:4.75:75, the average particle size was 60.50 nm, and the Zeta potential was −15.63 mV. There was no stratification after centrifugation at 4000 r∙min−1 for 10 min. Conclusion: The three kinds of ginsenoside Rg3 nanopreparations are sim-ple, stable and feasible. The stratification structure of ginsenoside Rg3 liposomes prepared by mi-croemulsion method is the most obvious.
文章引用:杨瑾, 邹丹, 梁蕾, 武艳玲, 张焕灵, 黄树峰. 人参皂苷Rg3负载PCL-PEG纳米系统在卵巢癌中的优化研究[J]. 临床医学进展, 2023, 13(3): 4531-4537. https://doi.org/10.12677/ACM.2023.133650

参考文献

[1] 柳鹏, 李勇. 人参皂苷生物活性的研究进展[J]. 中国生育健康杂志, 2004, 15(5): 317-319.
[2] Chen, X.J., Zhang, X.J., Shui, Y.M., Wan, J.B. and Gao, J.L. (2016) Anticancer Activities of Protopanaxadiol- and Protopanaxatriol-Type Ginsenosides and Their Metabolites. Evidence-Based Complementary and Alternative Medicine, 2016, Article ID: 5738694.
[3] 姚婵, 来茂德. 上皮间质转化(EMT)及其分子机制[J]. 国际遗传学杂志, 2006, 29(4): 290-294.
[4] Kalluri, R. (2009) EMT: When Epithelial Cells Decide to Become Mesenchymal-Like Cells. Journal of Clinical Investigation, 119, 1417-1419. [Google Scholar] [CrossRef
[5] 胡倩雯, 韩向晖. 中药干预肿瘤及纤维化疾病上皮间充质转化的研究进展[J]. 云南中医中药杂志, 2015, 36(3): 69-72.
[6] Liu, T., Zhao, L., Zhang, Y., et al. (2014) Ginsenoside 20(S)-Rg3 Targets HIF-1α to Block Hypoxia-Induced Epithelial-Mesenchymal Transition in Ovarian Cancer Cells. PLOS ONE, 9, e103887. [Google Scholar] [CrossRef] [PubMed]
[7] Li, J., Lu, J.J., Ye, Z.X., et al. (2017) 20(S)-Rg 3 Blocked Epi-thelial-Mesenchymal Transition through DNMT3A/miR- 145/FSCN1 in Ovarian Cancer. Oncotarget, 8, 53375-53386. [Google Scholar] [CrossRef] [PubMed]
[8] Li, J., Zhang, S.L., Pei, M.L., et al. (2018) FSCN1 Promotes Epi-thelial-Mesenchymal Transition through Increasing Snail1 in Ovarian Cancer Cells. Cellular Physiology and Biochemis-try, 49, 1766-1777. [Google Scholar] [CrossRef] [PubMed]
[9] Wang, C.Z., Anderson, S., Du, W., et al. (2016) Red Ginseng and Cancer Treatment. Chinese Journal of Natural Medicines, 14, 7-16.
[10] Zhou, Q.L., Zhu, D.N., Yang, X.W., et al. (2018) De-velopment and Validation of a UFLC-MS/MS Method for Simultaneous Quantification of Sixty-Six Saponins and Their Six Aglycones: Application to Comparative Analysis of Red Ginseng and White Ginseng. Journal of Pharmaceutical and Biomedical Analysis, 159, 153-165. [Google Scholar] [CrossRef] [PubMed]
[11] Chen, Z., Wei, X., Shen, L., et al. (2019) 20(S)-ginsenoside-Rg3 Reverses Temozolomide Resistance and Restrains Epithelial-Mesenchymal Transition Progression in Glioblastoma. Cancer Science, 110, 389-400. [Google Scholar] [CrossRef] [PubMed]
[12] Qiu, R., Qian, F., Wang, X., et al. (2019) Targeted Delivery of 20(S)-Ginsenoside Rg3-Based Polypeptide Nanoparticles to Treat Colon Cancer. Biomed Microdevices, 21, 18. [Google Scholar] [CrossRef] [PubMed]
[13] Wang, X.J., Zhou, R.J., Zhang, N., et al. (2019) 20(S)-ginsenoside Rg3 Sensitizes Human Non-Small Cell Lung Cancer Cells to Icotinib through Inhibition of Autophagy. European Journal of Pharmacology, 850, 141-149. [Google Scholar] [CrossRef] [PubMed]
[14] Peng, Y., Zhang, R., Yang, X., et al. (2019) Ginsenoside Rg3 Suppresses the Proliferation of Prostate Cancer Cell Line PC3 through ROS-Induced Cell Cycle Arrest. Oncology Letters, 17, 1139-1145. [Google Scholar] [CrossRef] [PubMed]
[15] Guo, Y.H., Kuruganti, R. and Gao, Y. (2019) Recent Advances in Ginsenosides as Potential Therapeutics against Breast Cancer. Current Topics in Medicinal Chemistry, 19, 2334-2347. [Google Scholar] [CrossRef] [PubMed]
[16] Bian, S., Zhao, Y., Li, F., et al. (2019) 20(S)-ginsenoside Rg3 Promotes HeLa Cell Apoptosis by Regulating Autophagy. Molecules, 24, 3655. [Google Scholar] [CrossRef] [PubMed]
[17] 董方言. 现代实用中药新剂型新技术[M]. 北京: 人民卫生出版社, 2001: 363-378.
[18] Mundargi, R.C., Babu, V.R., Rangaswamy, V., et al. (2008) Nano/Micro Technologies for Delivering Macromolecular Theapeutics Using Poly(D, L-lactide-co-glycolide)and Its Derivatives. Journal of Controlled Release, 125, 193-209. [Google Scholar] [CrossRef] [PubMed]
[19] Lu, J.M., Wang, X., Marin-Muller, C., et al. (2009) Current Advances in Research and Clinical Applications of PLGA Based Nanotecheology. Expert Review of Molecular Diagnos-tics, 9, 325-341. [Google Scholar] [CrossRef] [PubMed]
[20] 杨华, 易红. 我国微乳技术在药学领域中的研究进展[J]. 中国新药杂志, 2006, 15(10): 764-769.
[21] 胡译丽, 程国华. 抗肿瘤药物靶向制剂的研究进展[J]. 今日药学, 2021, 21(5): 317-320.